Incysus Therapeutics Announces Publication of U.S. Patent for Drug Resistant Immunotherapy (DRI) Technology
June 19, 2019 08:00 ET
|
Incysus Therapeutics, Inc.
US Patent and Trademark Office Issues U.S. Patent Covering Drug Resistant Immunotherapy (DRI) TechnologyClaims Provide Initial Protection for Incysus’ Novel DRI PlatformIncysus Controls Exclusive...
Fluidigm Scales Highly Multiplexed Cell Analysis with Introduction of Seven New Metal Markers
June 17, 2019 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Incysus Therapeutics to Present at Jefferies 2019 Global Healthcare Conference
May 22, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update
May 07, 2019 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in...
Autolus Announces Pricing of Public Offering
April 10, 2019 21:19 ET
|
Autolus Therapeutics plc
LONDON, April 10, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Proposed Public Offering in the United States
April 08, 2019 16:40 ET
|
Autolus Therapeutics plc
LONDON, April 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Bellicum Pharmaceuticals to Participate in Jefferies 6th Annual IO Cell Therapy Summit
March 27, 2019 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019
March 04, 2019 06:30 ET
|
Autolus Therapeutics plc
LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Ett nytt studieresultat med AroCell TK 210 ELISA vid prostatacancer har accepterats för publicering
February 25, 2019 02:30 ET
|
AroCell AB
Studien med titeln “The combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate prostate cancer from non-cancerous conditions”,...
New study results with AroCell TK 210 ELISA in prostate cancer has been accepted for publication
February 25, 2019 02:30 ET
|
AroCell AB
The study with the title “The combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate prostate cancer from non-cancerous...